Xenon Pharmaceuticals
Yahoo Finance • 21 days ago
Xenon to Present at Stifel 2025 Virtual CNS Forum
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing the... Full story
Yahoo Finance • last month
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to ini... Full story
Yahoo Finance • last month
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story
Yahoo Finance • last month
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Announces Proposed Public Offering
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of $2... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled,... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript November 8, 2023 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.75. Operator: Hello, thank you for standing... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced that its partner, Neurocrine Biosciences, Inc., reported today that the Pha... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2023 financial and operating results... Full story
Yahoo Finance • last year
13 Best Canadian Stocks to Buy and Hold
In this article, we will take a look at the 13 best Canadian stocks to buy and hold. To see more such companies, go directly to 5 Best Canadian Stocks to Buy and Hold. The Canadian economy is also facing the heat of inflation and rising i... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed effica... Full story
Yahoo Finance • last year
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neur... Full story
Yahoo Finance • 2 years ago
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechani... Full story
Yahoo Finance • 2 years ago
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key... Full story
Yahoo Finance • 2 years ago
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline Clinically important improvements seen for all patients across important subscales of S... Full story
Yahoo Finance • 2 years ago
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Wells Fargo 2023 Healthcare Conf... Full story
Yahoo Finance • 2 years ago
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last pa... Full story
Yahoo Finance • 2 years ago
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Confe... Full story
